Advertisement
Research Article| Volume 249, ISSUE 1, P86-94, November 01, 2006

Download started.

Ok

The acute treatment of nerve agent exposure

  • Kevin Cannard
    Correspondence
    4012 Dresden St., Kensington, MD 20895, United States. Fax: +1 301 319 9806, +1 240 481 5755 (Cell).
    Affiliations
    Walter Reed Army Institute of Research, Uniformed Services University of the Health Sciences, Walter Reed Army Medical Center, United States
    Search for articles by this author

      Abstract

      Nerve agents (NA) are simple and cheap to produce but can produce casualties on a massive scale. They have already been employed by terrorist organizations and rogue states on civilians and armed forces alike. By inhibiting the enzyme acetylcholine esterase, NAs prevent the breakdown of the neurotransmitter acetylcholine. This results in over-stimulation of muscarinic and nicotinic receptors in the autonomic and central nervous systems and at the neuromuscular junction. Increased parasympathetic stimulation produces miosis, sialorrhea, bronchospasm and bronchorrhea. Effects at the neuromuscular junction cause weakness, fasciculations, and eventually paralysis. Central effects include altered behavior and mental status, loss of consciousness, seizures, or apnea. Most deaths are due to respiratory failure. Treatment with atropine competitively blocks the parasympathetic effects. Oximes like pralidoxime salvage acetylcholine esterase by “prying off” NA, provided the attachment has not “aged” to an irreversible bond. This reverses weakness. Benzodiazepines like diazepam are effective against NA induced seizures. Mortality has been surprisingly low. If victims can survive the first 15 to 20 min of a vapor attack, they will likely live. The low mortality rate to date underscores that attacks are survivable and research reveals even simple barriers such as clothing offer substantial protection. This article reviews the properties of NAs and how to recognize the clinical features of NA intoxication, employ the needed drugs properly, and screen out anxious patients who mistakenly believe they have been exposed.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of the Neurological Sciences
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Trumpener U.
        The road to Ypres: the beginnings of gas warfare in World War I.
        J Mod Hist. 1975; 47: 460-468
        • Sidell F.
        • Takafuji E.
        • Franz D.
        Medical aspects of chemical and biological warfare.
        Office of the Surgeon General United States Army at TMM Publications, Washington, D.C.1997
        • Macilwain C.
        Study proves Iraq used nerve gas.
        Nature. 1993; 363: 3
        • Newmark J.
        The birth of nerve agent warfare: lessons from Syed Abbas Foroutan.
        Neurology. 2004; 62: 1590-1596
        • Kadivar H.
        • Adams S.C.
        Treatment of chemical and biological warfare injuries: insights derived from the 1984 Iraqi attack on Majnoon Island.
        Mil Med. 1991; 156: 171-177
        • Council UNS
        Report of the mission dispatched by the Secretary-General to investigate allegations of the use of chemical weapons in the conflict between the Islamic Republic of Iran and Iraq.
        United Nations, New York1984 (March 26)
        • Morita H.
        • Yanagisawa N.
        • Nakajima T.
        • Shimizu M.
        • Hirabayashi H.
        • Okudera H.
        • et al.
        Sarin poisoning in Matsumoto, Japan.
        Lancet. 1995; 346: 290-293
        • Ohbu S.
        • Yamashina A.
        • Takasu N.
        • Yamaguchi T.
        • Murai T.
        • Nakano K.
        • et al.
        Sarin poisoning on Tokyo subway.
        South Med J. 1997; 90: 587-593
        • Okudera H.
        Clinical features on nerve gas terrorism in Matsumoto.
        J Clin Neurosci. 2002; 9: 17-21
        • Okumura T.
        • Takasu N.
        • Ishimatsu S.
        • Miyanoki S.
        • Mitsuhashi A.
        • Kumada K.
        • et al.
        Report on 640 victims of the Tokyo subway sarin attack.
        Ann Emerg Med. 1996; 28: 129-135
        • United Nations
        Centre for Disarmament Affairs. Disarmament: the chemical weapons convention with selective index.
        United Nations, New York1994
        • Brennan R.J.
        • Waeckerle J.F.
        • Sharp T.W.
        • Lillibridge S.R.
        Chemical warfare agents: emergency medical and emergency public health issues.
        Ann Emerg Med. 1999; 34: 191-204
        • Craig F.N.
        • Cummings E.G.
        • Sim V.M.
        Environmental temperature and the percutaneous absorption of a cholinesterase inhibitor, VX.
        J Invest Dermatol. 1977; 68: 357-361
        • Cooper J.R.
        • Bloom F.E.
        • Roth R.H.
        The biochemical basis of neuropharmacology.
        8th ed. Oxford University Press, Oxford2003
        • Sidell F.R.
        • Groff W.A.
        The reactivatibility of cholinesterase inhibited by VX and sarin in man.
        Toxicol Appl Pharmacol. 1974; 27: 241-252
        • Nozaki H.
        • Hori S.
        • Shinozawa Y.
        • Fujishima S.
        • Takuma K.
        • Kimura H.
        • et al.
        Relationship between pupil size and acetylcholinesterase activity in patients exposed to sarin vapor.
        Intensive Care Med. 1997; 23: 1005-1007
        • LeBlanc F.N.
        • Benson B.E.
        • Gilg A.D.
        A severe organophosphate poisoning requiring the use of an atropine drip.
        J Toxicol Clin Toxicol. 1986; 24: 69-76
        • Goodman L.S.
        • Hardman J.G.
        • Limbird L.E.
        • Gilman A.G.
        Goodman and Gilman's the pharmacological basis of therapeutics.
        10th/ed. McGraw-Hill, New York2001
        • Defense USAMRIoC
        Nerve agents.
        in: Medical management of chemical casualties handbook. Third ed. USAMRICD, Chemical Casualty Care Division, Aberdeen Proving Ground, MD2000
        • Kawana N.
        • Ishimatsu S.
        • Kanda K.
        Psycho-physiological effects of the terrorist sarin attack on the Tokyo subway system.
        Mil Med. 2001; 166: 23-26
        • Leikin J.B.
        • Thomas R.G.
        • Walter F.G.
        • Klein R.
        • Meislin H.W.
        A review of nerve agent exposure for the critical care physician.
        Crit Care Med. 2002; 30: 2346-2354
        • Sidell F.R.
        Soman and sarin: clinical manifestations and treatment of accidental poisoning by organophosphates.
        Clin Toxicol. 1974; 7: 1-17
      1. Agency for Toxic Substances and Disease Registry A. Medical Management Guidelines (MMGs) for Nerve Agents: Tabun (GA; Sarin (GB); Soman; and VX. In: U.S. Dept. of Health and Human Services; 2006.

        • Marrs T.C.
        • Maynard R.L.
        • Sidell F.R.
        Chemical warfare agents: toxicology and treatment.
        Wiley, Chichester1996
        • Nozaki H.
        • Hori S.
        • Shinozawa Y.
        • Fujishima S.
        • Takuma K.
        • Sagoh M.
        • et al.
        Secondary exposure of medical staff to sarin vapor in the emergency room.
        Intensive Care Med. 1995; 21: 1032-1035
        • Woodall J.
        Tokyo subway gas attack.
        Lancet. 1997; 350: 296
        • Rotenberg J.S.
        • Newmark J.
        Nerve agent attacks on children: diagnosis and management.
        Pediatrics. 2003; 112: 648-658
        • Chyka P.A.
        • Seger D.
        • Krenzelok E.P.
        • Vale J.A.
        Position paper: single-dose activated charcoal.
        Clin Toxicol. 2005; 43: 61-87
        • Vale J.A.
        • Meredith T.J.
        • Heath A.
        High dose atropine in organophosphorus poisoning.
        Postgrad Med J. 1990; 66: 878
        • Holstege C.P.
        • Kirk M.
        • Sidell F.R.
        Chemical warfare. Nerve agent poisoning.
        Crit Care Clin. 1997; 13: 923-942
        • Amitai Y.
        • Almog S.
        • Singer R.
        • Hammer R.
        • Bentur Y.
        • Danon Y.L.
        Atropine poisoning in children during the Persian Gulf crisis. A national survey in Israel.
        JAMA. 1992; 268: 630-632
        • Tush G.M.
        • Anstead M.I.
        Pralidoxime continuous infusion in the treatment of organophosphate poisoning.
        Ann Pharmacother. 1997; 31: 441-444
        • Thompson D.F.
        Pralidoxime chloride continuous infusions.
        Ann Emerg Med. 1987; 16: 831-832
        • Kassa J.
        Review of oximes in the antidotal treatment of poisoning by organophosphorus nerve agents.
        J Toxicol Clin Toxicol. 2002; 40: 803-816
        • McDonough Jr., J.H.
        • Zoeffel L.D.
        • McMonagle J.
        • Copeland T.L.
        • Smith C.D.
        • Shih T.M.
        Anticonvulsant treatment of nerve agent seizures: anticholinergics versus diazepam in soman-intoxicated guinea pigs.
        Epilepsy Res. 2000; 38: 1-14
        • Nishiwaki Y.
        • Maekawa K.
        • Ogawa Y.
        • Asukai N.
        • Minami M.
        • Omae K.
        Effects of sarin on the nervous system in rescue team staff members and police officers 3 years after the Tokyo subway sarin attack.
        Environ Health Perspect. 2001; 109: 1169-1173
        • Yokoyama K.
        • Araki S.
        • Murata K.
        • Nishikitani M.
        • Okumura T.
        • Ishimatsu S.
        • et al.
        Chronic neurobehavioral effects of Tokyo subway sarin poisoning in relation to posttraumatic stress disorder.
        Arch Environ Health. 1998; 53: 249-256